Rapport Therapeutics
PublicRapport Therapeutics is now publicly traded
The data on this page reflects Rapport Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Jun 6, 2024
Last Round
Series B
Aug 23, 2023
Total Funding Raised
$424.4M
Company Overview
Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small molecule precision medicines for central nervous system (CNS), neurological, and psychiatric disorders. The company's proprietary RAP (receptor-associated proteins) technology platform allows for the specific targeting of receptors in distinct neuroanatomical regions, aiming to create treatments with better efficacy and fewer side effects than existing therapies. Its lead program, RAP-219, is in clinical trials for conditions including drug-resistant focal onset seizures and bipolar mania. Founded in 2022, the company went public in June 2024 and trades on the Nasdaq under the ticker RAPP.
Sector
Healthcare
AI Layer
Non-AI
Keywords
Rapport Therapeutics Comparables
Compare Rapport Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tenacia Biotechnology | 71% | |
| Newleos Therapeutics | 68% | |
| NeuShen Therapeutics | 46% | |
Rapport Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Jun 6, 2024 | ||||
| Series B | Aug 23, 2023 | ||||
| Series A | Mar 7, 2023 |
Rapport Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Jefferies | IPO |
| Perceptive Advisors | Series B |
| Fidelity Management & Research Company | Series B |
| TD Cowen | IPO |
| Invus Opportunities | Series A |
| Logos Capital | Series B |
| ARCH Venture Partners | Series A, Series B, IPO |
Rapport Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
